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Összefoglalás 
Célkitűzés: Az antihipertenzív gyógyszerek pszichológiai hatásával kapcsolatban  
rendelkezésre álló adatok ellentmondásosak. Vizsgálatunk célja a korszerű antihipertenzív 
kezelés pszichometriai paraméterekre és szérum brain-derived neurotrophic factor (BDNF) 
szintre kifejtett hatásának vizsgálata volt  
Módszerek: Gyógyszeres kezelést nem kapó hipertóniás betegekben (HT, n=31) a 
gyógyszeres kezelés előtt, majd azt követően három hónappal, valamint egészséges 
kontrollokban (CONT, n=22) egyszeri alkalommal vizsgáltunk pszichometriai, 
hemodinamikai, artériás érfalmerevség és vérvételi paramétereket. Az alanyok az alábbi 
pszichometriai teszteket töltötték ki: Beck Depresszió Kérdőív (BDI), Hamilton Szorongás 
Skála (HAM-A), SCL-90-R Kérdőív (SCL-90), Temperamentum Kérdőív, Big 5 Kérdőív, 
Fájdalom-vigilancia és Tudatosság Kérdőív, Berkeley Kifejezőkészség Kérdőív. Amlodipin 
és/vagy perindopril alapú volt az antihipertenzív kezelés. A szérum BDNF szint mérése 
ELISA-val történt.  
Eredmények: Három hónapos antihipertenzív kezelés hatására a brachiális szisztolés 
vérnyomás (153.3±15.9 Hgmm versus 129.5±10.0 Hgmm) és a pulzushullám terjedési 
sebesség (8.2±1.4 m/s versus 7.5±1.6 m/s) is szignifikánsan csökkent. Ezzel párhuzamosan 
szignifikáns javulást találtunk a BDI pontszámban (0,73 pont)  és számos SCL-90 alskálában. 
A szérum BDNF szint nem különbözött a CONT és a HT csoportok között és nem változott a 
gyógyszeres kezelés hatására.  
Következtetések: Eredményeink arra utalnak, hogy még gyógyszeres kezelést nem kapó 
hipertóniás betegekben a jelenleg javasolt antihipertenzív hatóanyagok bevezetése egyaránt 
jótékony hatással lehet a pszichés státusra és az életminőségre.    
 
 
3 
 
Abstract 
Aims: Current evidence on the psychological effects of antihypertensive medications is 
controversial. The aim of this study was to evaluate the effect of current antihypertensive 
medication on different psychometric parameters and on serum brain-derived neurotrophic 
factor (BDNF) level. 
Methods: Psychometric, haemodynamic, arterial stiffness and laboratory parameters were 
evaluated before and 3 months after the initiation of antihypertensive medication in untreated 
hypertensive patients (HT, n=31), and once in healthy controls (CONT, n=22). Subjects 
completed the following psychometric tests: Beck Depression Inventory (BDI), Hamilton 
Anxiety Scale (HAM-A), Symptom Checklist 90 Revised (SCL-90), Temperament Evaluation 
of Memphis, Pisa, Paris, and San Diego Autoquestionnaire, Big Five Inventory, Pain 
Vigilance and Awareness questionnaire and Berkeley Expressivity Questionnaire. Amlodipine 
and/or perindopril compounds were preferred medications. Serum BDNF was measured with 
ELISA. 
Results: Brachial systolic blood pressure, as well as pulse wave velocity were significantly 
improved in the HT group over the 3 months follow-up (153.3±15.9 mmHg vs. 129.5±10.0 
mmHg and 8.2±1.4 m/s vs 7.5±1.6 m/s, respectively). Similarly, we found improvements in 
BDI (0.73 points) and in several Scl-90 subscales. Serum BDNF was not different between 
CONT and HT and did not change for therapy. 
Conclusions: Our results indicate that initiation of currently recommended antihypertensive 
medications in newly diagnosed patients may have a significant impact on psychological 
well-being of patients and could influence quality of life as well.  
Keywords: antihypertensive medication, depression, arterial stiffness, psychiatric symptoms, 
affective temperaments, brain-derived neurotrophic factor 
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List of abbreviations 
AIx: augmentation index  
ARB: angiotensin II receptor blocker 
BDI: Beck Depression Inventory 
BFI-44: Big Five Qestionnaire 
BMI: body mass index 
Cyclothymic temp. score: cyclothymic affective temperament score 
DBPbrach: brachial diastolic blood pressure 
GFR-EPI: glomerular filtration rate assessed by the chronic kidney disease 
epidemiology collaboration glomerular filtration rate equation 
HAM-A: Hamilton Anxiety Scale 
HR: heart rate 
Hyperthymic temp. score: hyperthymic affective temperament score 
PPAmp: pulse pressure amplification 
PPbrach: brachial pulse pressure 
PPcentr: central pulse pressure 
PPB: brachial pulse pressure 
PWV: pulse wave velocity 
SCL-90: Symptom Checklist-90 Questionnaire 
SBPbrach: brachial systolic blood pressure 
SBPcentr: central systolic blood pressure 
TEMPS-A: The Temperament Evaluation of Memphis Pisa, Paris and San Diego 
questionnaire 
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Introduction 
 
A causal relationship between elevated blood pressure and cardiovascular morbidity/mortality 
has been clearly demonstrated (Lewington et al., 2002). If lifestyle modifications by 
themselves are insufficient to treat hypertension, pharmacological interventions are required 
to control blood pressure and avoid late cardiovascular complications. This decision is a 
complex procedure, where  severity of hypertension, age of the patient, presence of 
comorbidities, total cardiovascular risk, and additional features of different drug classes must 
also be taken into consideration (Mancia et al., 2013).  
Antihypertensive medications from different pharmacological classes may cause different side 
effects. In contrast, different agents can also have unexpected beneficial effects. For example 
losartan may be beneficial in gout patients (Wurzner et al., 2001) or nebivolol may improve 
erectile dysfunction (Fongemie and Felix-Getzik, 2015). While impact of antihypertensive 
agents on psychological symptoms had also been studied, results are controversial. Case 
reports demonstrated depressive effects of the beta-blocker propranolol and timolol (McNeil 
et al., 1982; Nolan, 1982). Furthermore, more frequent use of antidepressants was observed in 
patients taking beta-blockers (Avorn et al., 1986).  A case control study of incident depression 
cases and population-based controls however found a null-effect after  adjusting for potential 
confounders including co-morbidities (Bright and Everitt, 1992). Similarly, the ACE-inhibitor 
enalapril was found to have a depressive effect in a case report (Patterson, 1989), however 
another small-scale study suggested an antidepressive impact of enalapril (Braszko et al., 
2003). Calcium channel blockers have been suggested to be associated with increased 
incidence of mood disorders (Hallas, 1996), but others could not confirm these findings 
(Dunn et al., 1999; Patten et al., 1995). Most of the above-mentioned studies were case 
reports or were based on prescription databases allowing for potential bias and confounding. 
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Furthermore, they investigated older agents that are not state-of-the-art any more. 
Surprisingly, no data are available about the psychosomatic impact of currently preferred 
medications, such as perindopril or amlodipine in incident hypertensive patients who are free 
from mood disorders. 
Different personality traits or dimensions can also influence cardiovascular diseases or risk 
factors. Trait anger was found to be associated with arterial stiffness in men (Williams et al., 
2006), dominant cyclothymic affective temperament showed correlation with chronic 
hypertension and with acute coronary events in hypertensive patients (Eory et al., 2014a; Eory 
et al., 2014b) and cyclothymic temperament score is an independent determinant of brachial 
systolic blood pressure in chronic hypertension (Laszlo et al., 2016). However, no data are 
available about the stability of different dimensions of personality around the initiation of 
antihypertensive medications.  
Brain-derived neurotrophic factor (BDNF), a member of the neurotrophic factor family, plays 
an important role in the regulation of neuronal growth, maintenance and survival (Mattson et 
al., 2004). It's involvement in psychiatric disorders is fundamental and was confirmed by a 
meta-analysis, as in major depressive disorder the decreased serum BDNF (seBDNF) level 
was elevated following a course of antidepressant treatment (Sen et al., 2008). It is 
hypothesized to play a protective role in cardiovascular pathophysiology as its higher serum 
level was found to be associated with decreased risk of cardiovascular disease and mortality 
(Kaess et al., 2015). Recently, we found elevated seBDNF in chronic hypertension (Nemcsik 
et al., 2016), but its level in drug-free hypertensive patients and its changes for 
antihypertensive therapy has never been studied yet.   
The aim of our study was to evaluate the effect of modern antihypertensive medications, 
based mostly on perindopril and/or amlodipine on depression, anxiety, psychiatric symptoms, 
affective temperaments and different other dimensions of personality and seBDNF level. We 
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hypothesized a positive impact of these modern medications on depression, anxiety, the 
intensity of psychiatric symptoms in different psychopathological dimensions and seBDNF, 
and the stability of affective temperaments and other dimensions of personality.  
 
Methods 
Patients 
This was a cross-sectional and prospective study in two urban primary care practices, between 
August 2013 and February 2016. In the cross-sectional part Caucasian patients with medically 
untreated essential hypertension, grade 1 or 2 (HT) and healthy controls (CONT) were 
included.  Among HT, grade I hypertensive patients who were already in care and trained for 
lifestyle modifications previously and newly recognized hypertensive patients were also 
involved. In the HT group patients with atrial fibrillation, treated depression, anxiety or with 
dementia potentially interfering with the completion of questionnaires were excluded. In case 
of CONT denial of consent was the only exclusion criterion. During the screening visit, when 
the patient was evaluated for hypertension signed informed consent was obtained. Then 
questionnaires were given to the patients, home blood pressure monitoring (HBPM) or 
ambulatory blood pressure monitoring (ABPM) were initiated and an appointment within a 
week for arterial stiffness measurement and blood sampling was scheduled. Based on HBPM, 
or ABPM results subjects with white coat hypertension were excluded. If the effect of 
lifestyle modification was unable to control blood pressure values or the patient reported 
hypertension-related symptoms or either risk factors or absolute cardiovascular risk required 
treatment, antihypertensive drug therapy was initiated based on the current guideline (Mancia 
et al., 2013).  
The choice of the antihypertensive agent was personalized taking into account the age, sex, 
comorbidities and grade of hypertension, and was based on the recent European guideline as 
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well (Mancia et al., 2013). Amlodipine from the calcium channel blocker group, perindopril 
from the ACE-inhibitor group and indapamide from the diuretic group were used as first line 
agents. When indicated, bisoprolol, carvedilol, nebivolol or long-lasting metoprolol were the 
preferred beta-blockers. In subjects with gout the uricosuric angiotensin receptor blocker 
(ARB) losartan was initiated, if an ARB was considered. When more than one agent was 
necessary we preferentially initiated the single-pill combination of perindopril and 
amlodipine. Within 10 days after the initiation of antihypertensive therapy, patients had a 
follow-up visit and therapy was modified if necessary. 
All 31 hypertensive patients took part in the prospective part of the study, when all baseline 
measurements were repeated 3 months after the initiation of antihypertensive medication. No 
untreated hypertensive control group was formed, as we thought that it would be unethical to 
withhold antihypertensive treatment in a population with symptomatic or more severe 
hypertension. Routine laboratory, psychometric and arterial stiffness parameters were 
evaluated at baseline for hypertensive and control patients. The hypertensive group also had 
repeat measurements after 3 months of therapy. 
The study was approved by the Scientific and Research Ethics Committee of the Medical 
Research Council, the Hungarian Ministry of Health (ETT TUKEB 842/PI/2011) and was 
carried out in accordance with the tenets of the Declaration of Helsinki. 
 
Evaluation of different psychometric parameters 
The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report 
questionnaire and is one of the most widely used instruments for assessing depression 
severity. Participants are asked to make ratings on a four-point scale, where a higher score 
correlates with more severe depression (Beck et al., 1961).  
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The Hamilton Anxiety Scale (HAM-A), evaluated by the examiner was used to study the 
severity of anxiety. The scale consists of 14 items, each item is scored on a scale of 0 (not 
present) to 4 (severe anxiety) (Hamilton, 1959).  
The Symptom Checklist 90 Revised (SCL-90), a self-rated test consisting of 90 multiple-
choice items ranging 0–4 (Delogatis, 1994) was used to identify the presence and quantify the 
intensity of psychiatric symptoms distributed among 9 psychopathological dimensions: 1) 
somatization; 2) obsessiveness–compulsiveness; 3) interpersonal sensitivity; 4) depression; 5) 
anxiety; 6) hostility; 7) phobic anxiety; 8) paranoid ideation; 9) psychoticism. The instrument 
has three global indices of distresses as well: the global severity index (GSI), the positive 
symptom distress index (PSDI) and the positive symptom total (PST).  
The Temperament Evaluation of Memphis, Pisa, Paris and San Diego Autoquestionnaire 
(TEMPS-A) was used to assess affective temperaments on depressive, cyclothymic, 
hyperthymic, irritable and anxious subscales, requiring ‘yes’ (score 1) or ‘no’ (score 0) 
answers (Akiskal et al., 2005). TEMPS-A, which contains 110 items (109 in the version for 
males), has been extensively studied, translated into more than 25 languages and validated in 
several of the latter.  
The Big Five Inventory (BFI-44) was used to measure the five big dimensions of personality; 
extraversion, agreeableness, conscientiousness, neuroticism and openness (John and 
Srivastava, 1999). On the 44-item questionnaire, each item is answered on a 5-point scale 
ranging from 1 (strongly disagree) to 5 (strongly agree). 
The Berkeley Expressivity Questionnaire (BEQ) was used to evaluate the subjects' emotional 
expressivity. The 16-item scale is separated into 3 facets: negative expressivity, positive 
expressivity and impulse strength (Gross and John, 1997). Each item is answered on a 7-point 
scale ranging from 1 (strongly disagree) to 7 (strongly agree).  
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The Pain Vigilance and Awareness Questionnaire (PVAQ), a 16-item instrument was used to 
measure the subjects' pain vigilance and awareness (Roelofs et al., 2003). All items are rated 
on a scale: 0 (never) to 5 (always).  
 
Measures of blood pressure and arterial stiffness  
Measurements were performed in a temperature-controlled room, between 7.00 and 8.00 a.m. 
prior to blood collection. Patients were required to fast overnight and refrain from smoking 
and drinking caffeine-containing beverages before the procedure, but to take their usual blood 
pressure medication (only at the follow-up visit). Upon arrival and after a 5-minute rest, two 
brachial blood pressure measurements were taken on each arm in the sitting position with a 
validated oscillometric blood pressure device (Omron M3). The mean value from the arm 
with the higher systolic value was further used as brachial systolic (SBPbrach) and diastolic 
(DBPbrach) blood pressure and heart rate. Brachial pulse pressure (PPbrach) was also 
calculated from these data. The subjects were next fitted with an arterial stiffness 
measurement device and were asked to rest in the supine position for approximately 15 
minutes before being measured. Arterial stiffness and central haemodynamic parameters were 
evaluated with the gold-standard tonometric method (PulsePen, DiaTecne, Milan, Italy) (Salvi 
et al., 2004). This method provides estimates of pulse wave velocity (PWV), augmentation 
index (Aix), central systolic blood pressure (SBPcentr), and central pulse pressure (PPcentr). 
In each subject, two sequences of arterial stiffness measurements were performed and their 
mean was used for statistical analysis. In PWV calculations, 80% of the carotid-femoral 
distance was used, according to the most recent recommendation (Van Bortel et al., 2012). 
The intra- and interobserver variability of PWV measurements obtained by the PulsePen 
device in hypertensive patients was 4.6 and 6.3%, respectively. Since PulsePen calculates 
pressures based on brachial diastolic blood pressure calibration, the calculated central 
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diastolic blood pressure is identical to the brachial diastolic blood pressure assessed in the 
supine position (Salvi et al., 2004).  
Measurement of seBDNF concentration 
Peripheral blood samples of patients were collected in anticoagulant-free tubes, right after the 
measurement of arterial stiffness. After centrifugation (3600 rpm for 6 min) the serum was 
stored at −20°C. SeBDNF was measured using commercially available sandwich enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis MN, USA) according to the 
manufacturer's protocol and serum BDNF level was determined in ng/mL. 
Statistical analysis 
Normality of the parameters was tested with the Kolmogorov-Smirnov test. Descriptive 
characteristics, laboratory, arterial stiffness, haemodynamic parameters and psychometric 
scores were compared between CONT and HT groups using 2-sample Student's t-tests or 
independent samples Mann–Whitney rank-sum test for data failing tests of normality at 
baseline. Laboratory, arterial stiffness, haemodynamic and psychometric variables were 
compared between baseline and follow-up within the HT group using paired Student's–t-tests 
or dependent samples Mann–Whitney rank-sum test for data failing tests of normality. We 
also run a sensitivity analysis on participants with already known hypertension under our care 
who received lifestyle education before study initiation to minimize study effect related to 
care initiation and education. 
Data are expressed as mean ± standard deviation or median with interquartile ranges. For 
psychometric parameters with non-normal distribution mean with interquartile ranges are 
presented. P<0.05 was considered to be significant. SPSS 22.0 for Windows was used for all 
calculations.  
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Results  
Altogether 31 patients with hypertension and 22 controls were included in the cross-sectional 
analysis. 15 of the 31 hypertensive patients were already in hypertension care and  were 
previously educated for lifestyle modifications. The rest 16 of them were educated around 
study involvement. All 31 hypertensive patients completed the 3-month follow-up and were 
included in the longitudinal analysis.  
The final antihypertensive and vasculoprotective medications of the hypertensive group at 
follow-up are shown in table 1. More than 80% of the patients received the ACE-inhibitor 
perindopril and three-quarter the calcium-channel blocker amlodipine. Only 4 patients were 
on indapamide therapy, 2 of them took the ARB losartan. Altogether 12 patients required 
beta-blockers and bisoprolol was the most frequently used. Only one patient received 
additional blood pressure lowering drug (doxazosin). Equally 3 patients were on statin and 
acetylsalicylic acid therapy, but none of them were initiated parallel with the antihypertensive 
medication. Most of the patients were on a dual combination of antihypertensive agents. In 
the hypertensive group 4 patients (12.9%) were treated for gastroesophageal reflux disease, 3 
patients (9.7%) for hypercholesterinaemia, equally 2 patients (6.4%) had gout, bronchial 
asthma, inflammatory bowel disease or non-pharmacologically treated type 2 diabetes and 1 
patient (3.2%) had peripheral artery disease.  
Baseline demographic, laboratory, haemodynamic and arterial stiffness parameters are shown 
in Table 2. CONT subjects were younger than HT subjects. Their waist circumference, BMI, 
blood glucose, uric acid, total cholesterol and triglyceride levels were lower that of 
hypertensive patients’ at baseline. No significant changes in these parameters were found after 
3 months of antihypertensive treatment. All brachial and central haemodynamic and arterial 
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stiffness parameters were impaired in hypertensive compared with control subjects and all 
improved significantly with blood pressure medication. 
Table 3. demonstrates psychometric measures of the groups at baseline and follow-up. 
Anxiety measured by HAM-A, somatization, obsessiveness-compulsiveness and positive 
symptom distress index measured by SCL-90 and overall emotional expressivity and negative 
emotional facet scores of the Berkeley Expressivity Questionnaire were significantly different 
between the hypertensive and control groups. After 3 months of antihypertensive treatment 
depression score measured by BDI improved significantly with 0.73 points. Many SCL-90 
dimensions also improved during follow-up, such as somatization, obsessiveness-
compulsiveness, interpersonal sensitivity, anxiety, psychoticism, the global severity index and 
the positive symptom total. 
Our sensitivity analysis on 15 patients already under care for hypertension before study 
initiation showed similar point estimates to the main analysis although some of the changes 
did not reach statistical significance (results are available on request.) 
 
Discussion 
The results of the present study demonstrated, that in newly diagnosed hypertensive patients 
free from psychiatric disorders the initiation of currently recommended antihypertensive 
medications markedly improves blood pressure and arterial stiffness and also beneficially 
effects depression and psychiatric symptoms in different directions of psychopathological 
dimensions, besides unchanged seBDNF.  
Angiotensin-converting enzyme (ACE) mediates the production of angiotensin II, which, 
throughout its brain receptors besides its important role in blood pressure control (Unger et 
14 
 
al., 1988) also participates in the regulation of mood (Gard et al., 1999). In our study, more 
than 80% of the hypertensive patients received the ACE-inhibitor perindopril. In contrast to 
enalapril, perindopril due to its high lipophilicity and central nervous system (CNS) 
permeability, is regarded as centrally active agent. It has been found to ameliorate cognitive 
impairment in an animal model of vascular dementia (Yamada et al., 2011). However, its 
antidepressant effect has not been studied so far. 
More than 70% of our patients were taking the calcium channel blocker amlodipine therapy. 
According to a previous study in hypertensive patients with coronary artery disease, 
verapamil-based treatment improved depressive symptoms during one-year follow-up (Ried et 
al., 2005). Similarly to verapamil and perindopril, amlodipine also penetrates into the CNS, 
where it may have beneficial pleiotrophic effects, such as potentiating the antiepileptic effect 
of lamotrigine, suggested by an animal study (Luszczki et al., 2007). Moreover, in 
spontaneously hypertensive rats the concomitant administration of amlodipine and 
atorvastatin improves cognitive dysfunction and exerts antioxidant effects in the hippocampus 
and in the rostral ventricular medulla (Kishi and Sunagawa, 2012). Although animal data are 
accumulating on the neuroprotective role of amlodipine in the CNS, no data are currently 
available regarding its effect on psychometric parameters in humans. Therefore our data are 
the first to show the possible beneficial psychiatric effect of perindopril and amlodipine, two 
very popular antihypertensive medications. 
Another possible pathophysiological mechanism that may explain our findings may be the 
influence of the used medications on the hypothalamic-pituitary-adrenal (HPA) axis, which 
plays an important role in depression and other psychopathological conditions as well as in 
cardiovascular pathology (Penninx, 2016). In animal models both the administration of the 
ACE-inhibitor ramipril or different calcium channel blockers were found to reduce HPA axis 
activity (Kumar et al., 2012; Raasch et al., 2006).  
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The possible effect of neurotrophins has never been studied in this context yet. Although we 
recently reported, that in treated chronic hypertension seBDNF is elevated compared with 
controls and chronic hypertension is an independent determinant of seBDNF (Nemcsik et al., 
2016), but in our study seBDNF was not elevated in untreated hypertensive patients. 
Previously perindopril and the combination of amlodipine and irbesartan were both found to 
modify BDNF beneficially on cellular level (Ali et al., 2016; Hasegawa et al., 2016), but 
contrary to expectations, in our study seBDNF was unchanged after three months of mostly 
perindopril and/or amlodipine based therapy, although a tendency of increase appeared. As in 
our previous study the average duration of hypertension was 11 years (Nemcsik et al., 2016), 
it is plausible, that seBDNF elevation is not an acute event, but might be a part of a long-term 
compensatory process. Longer follow-up and higher number of untreated hypertensive 
patients involved would be required to clarify this question as well as the possible impact of 
particular antihypertensive agent groups on seBDNF.     
Personality is thought to be relatively stable throughout the lifespan, but their quantitative 
changes considered important research question (Ibanez et al., 2016). Temperament is 
regarded as an inherited part of personality and represents the biologically stable core of 
emotional reactivity (Bouchard, 1994); although, there is an ongoing discussion regarding the 
influence of age on depressive temperament with differences between men and women 
(Vazquez et al., 2012). Furthermore, psychoactive medications were found to have an effect 
on personality measures. For example, paroxetine was shown to have a specific 
pharmacologic effect on measures of neuroticism and extraversion in major depressive 
disorder independent from its effect on depression (Tang et al., 2009). Based on these 
findings, it seemed to be reasonable to study the potential effect of centrally active currently 
recommended antihypertensive medications on personality. In the present study no significant 
changes in affective temperaments and in the big five dimensions of personality were found 
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after the initiation of antihypertensive medications, thus our results may indicate that these 
agents do not influence measures of these personality constructs. 
It is important to note that low levels of blood pressure can also be associated with depression, 
especially in the elderly (Kim et al., 2010). Moreover, according to a study performed in 
elderly subjects between 1991 and 1995, low diastolic blood pressure and a decrease of either 
systolic or diastolic blood pressure during a two-year follow-up was associated with an 
increase of depressive symptoms. While only 25% of patients took any antihypertensive 
medications (very likely old-type agents), the results were unchanged when patients on 
antihypertensive medications were excluded from analysis (Paterniti et al., 2000). No cut-off 
blood pressure values were reported below which severity of depressive symptoms would 
worsen so far, as in both studies arbitrary blood pressure categories were used based on the 
study sample (the lowest 10 percentile (Kim et al., 2010) or the first quartile (Paterniti et al., 
2000) of systolic/diastolic blood pressure). It is also important to note, that in both of these 
studies the mean age of subjects was 65, which is much higher compared with our study. We 
suppose that in younger patients the correction of elevated blood pressure with currently 
recommended medications may have beneficial psychological impact while with aging very 
low blood pressure may be associated with psychopathological and somatic symptoms.  
Arterial stiffness and central blood pressure were also measured in our patients. Carotid-
femoral pulse wave velocity, the most accepted arterial stiffness parameter is recommended 
for cardiovascular risk prediction both in the recent European Hypertension Guideline and in 
an American Heart Association scientific statement (Mancia et al., 2013; Townsend et al., 
2015). As pulse wave velocity changes slowly, the remarkable decrease observed in the 
present study reflects the good medication compliance of our participants. 
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 There are data available about the possible association between arterial stiffness and mood 
disorders. In a population-based cross-sectional study Tiermeier et al. found, that patients with 
increased arterial stiffness were more likely to have depressive symptoms. The authors 
concluded that arterial stiffening may partly explain the proposed relationship between 
vascular factors and depression (Tiemeier et al., 2003). Moreover, in middle-aged patients 
arterial stiffness measured by the augmentation index was found to be associated with anxiety 
sensitivity (Seldenrijk et al., 2013). Less data is available about the association between 
arterial stiffness and personality traits: low hyperthymic affective temperament score was 
found to be associated with an increased level of arterial stiffening (Laszlo et al., 2016), while 
high trait anger was found to be associated with arterial stiffness in men (Williams et al., 
2006). Whether initial arterial stiffness or its changes are related to the observed improvement 
of depression and psychiatric symptoms and whether they are related to the antihypertensive 
medications used in our study are questions that require further studies with large samples.  
There are several limitations of our study. First, the number of patients involved limits the 
potential for multivariable analysis by adjusting for potential confounders. As the medication 
of the patients was heterogeneous, the individual contribution of different agents cannot be 
identified. Additionally, as the follow-up period was only 3 months, the stability of the 
observed changes in a longer time period still has to be investigated. Moreover, although our 
methodology used standardized questionnaires and excluded patients with dementia, a 
complete exclusion of misinterpretations or mistakes by patients is nevertheless impossible. 
Finally, as our study had a non-controlled design, we investigated the effect of at least 2 types 
of interventions: medication effect and study effects related to initiation of care (like 
education or discussion with the physician and nurses). Although it is impossible to entangle 
the individual effect of these interventions, our sensitivity analysis suggest that medication 
initiation provides a substantial portion of the observed changes in psychometric and 
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biological parameters. The major limitation is that, due to ethical considerations it is an 
uncontrolled study without a proper control group for the follow-up period.  
 
Conclusions 
In conclusions, currently recommended antihypertensive medications, based on perindopril 
and/or amlodipine might have beneficial impact on depression and on the intensity of 
numerous psychiatric symptoms. If these effects are confirmed in other studies, they may 
broaden the range of factors considered when antihypertensive medications are selected.   
However, the contribution of identical agents or the regular patient care itself and the 
persistence of these effects on longer period of time still needs to be clarified. 
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Table 1. Antihypertensive and vasculoprotective medications of HT2 group. 
 
Regular medications N (total=31) 
ACE inhibitor (perindopril) 26 (83.9 %) 
Angiotensin-receptor blocker (losartan) 2 (6.5 %) 
Calcium channel blocker (amlodipine) 22 (71.0 %) 
Beta-blockers 12 (38.7 %) 
bisoprolol 7 (22.6 %) 
carvedilol 2 (6.5 %) 
metoprolol 1 (3.2 %) 
nebivolol 2 (6.5 %) 
Alfa-adrenergic receptor blocker (doxazosin) 1 (3.2 %) 
Diuretic (indapamid) 4 (12.9 %) 
Antiplatelet medications 3 (9.7 %) 
Statins 3 (9.7 %) 
1 type of antihypertensive agent 4 (12.9 %) 
2 types  of antihypertensive agents 19 (61.3 %) 
3 types of antihypertensive agents 6 (19.4 %) 
4 types of antihypertensive agents 2 (6.4 %) 
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Table 2. Demographic, laboratory, haemodynamic and arterial stiffness parameters of 
controls (CONT) and hypertensive patients at baseline (HT1) and during therapy (HT2). 
 CONT HT1 HT2 
Subjects [man/woman] 
22 (8/14) 31 (22/9) 31 (22/9) 
Age [year] 31 (26-41.2) 47 (38-63)* 48 (39-63) 
Smoking [n (%)] 4 (18.2%) 10 (32.3%) 10 (32.3%) 
Waist circumference [cm] 83 (77-93) 98.5 (91-105)* 97 (94-104.5) 
BMI [kg/m2] 22.9 (2.9) 28.6 (5.4)* 28.3 (5.4) 
Blood glucose [mmol/l] 4.9 (4.7-5.3) 5.1 (4.8-5.9)* 5.4 (4.9-5.5) 
eGFR-EPI [mmol/l] 87.1 (19.9) 88.4 (17.1) 88.0 (17.6) 
Uric acid [µmol/l] 299.9 (76,6) 357.9 (79.2)* 381.2 (97.6) 
Total cholesterol [mmol/l] 4.8 (0.79) 5.9 (1.04)* 5.6 (1.04) 
Triglyceride [mmol/l] 0.8 (0.28) 1.9 (0.83)* 1.9 (1.06) 
SBPbrach [Hgmm] 117.1 (10.1) 153.3 (15.9)* 129.5 (10.0)# 
DBPbrach [Hgmm] 70 (64-71.2) 91.5 (85.6-99.2)* 80.5 (73.5-85)# 
PPbrach [Hgmm] 49.7 (8.2) 57.9 (11.3)* 50.6 (10.2)# 
Heart rate [1/min] 68.1 (9.3) 79.7 (12.5)* 74.5 (9.3)# 
SBPcentr [Hgmm] 112.4 (8.4) 138.1 (14.2)* 121 (11.5)# 
DBPcentr [Hgmm] 65.9 (6.8) 84.4 (8.5)* 74.7 (7.6)# 
PPcentr [Hgmm] 46.5 (7.6) 53.8 (12.1)* 46.3 (10.4)# 
Augmentation index [%] 1.7 (13.2) 18.3 (16.8)* 10.1 (17.3)# 
PWV [m/sec] 6.2 (0.9) 8.2 (1.4)* 7.5 (1.6)# 
seBDNF (ng/ml) 22.7 (20.4-26.2) 22.1 (18.2-28.7) 23.9 (17.9-28.4) 
 
 
Continuous data are presented as mean (± SD) or medians (25-75 percentiles). CONT: control 
subjects; HT1: hypertensive patients before blood pressure medication; HT2: treated 
hypertensive patients 3 months after initiation of medication. BMI: body mass index; eGFR-
EPI: glomerular filtration rate assessed by the chronic kidney disease epidemiology 
collaboration glomerular filtration rate equation; SBPbrach: brachial systolic blood pressure; 
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DBPbrach: brachial diastolic blood pressure; PPbrach: brachial pulse pressure; SBPcentr: 
central systolic blood pressure; DBPcentr: central diastolic blood pressure; PPcentr: central 
pulse pressure; PWV: pulse wave velocity; seBDNF: serum brain-derived neurotrophic factor. 
* p<0.05 between CONT-HT1; # p<0.05 between HT1-HT2.  
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Table 3. Comparison of psychometric scores of hypertensive at baseline and during therapy 
and control patients. 
 CONT HT1 HT2 
BDI 3.8 (0-6) 5.1 (2-8) 4.4 (0-7)# 
HAM-A 4.1 (4.1) 6.4 (6.0)* 7.8 (8.0) 
SCL-90-R    
Somatization 2.7 (1-4) 8.7 (3.7-13.5) * 5 (2-6) # 
Obs-comp 10.5 (3.9) 14.9 (10-17.2) * 12.1 (8.7-14) # 
Interpersonal sensitivity 3.4 (0.2-5) 5.1 (0-7.2) 3.5 (0-6.5) # 
Depression 4.8 (2-5.7) 5.8 (0-5.7) 4.2 (0-4.5) # 
Anxiety 2.9 (1-4.7) 5.2 (0.7-8.2) 3.5 (0-6.5) # 
Hostility 1.6 (0-2.7) 2.2 (0-2) 1.5 (0-2) 
Phobic anxiety 0.5 (0-1) 1.6 (0-2) 1.4 (0-2) 
Paranoid ideation 1.5 (0-2) 2.9 (0-4.2) 2.6 (0-3.2) 
Psychoticism 1.5 (0-2) 3.6 (0-4.2) 1.7 (0-2) # 
GSI 0.3 (0.1-0.4) 0.5 (0.1-0.6) 0.4 (0.1-0.5)# 
PSDI 1.3 (1.1-1.4) 1.6 (1.1-1.8) * 1.5 (1.1-2) 
PST 17.9 (10-26) 23.5 (10-27.2) 19.8 (5.7-32)# 
TEMPS-A    
Depressive 6.6 (5-8) 6 (4-8) 6.2 (3-8) 
Irritable 4.1 (2-5) 4.4 (2-6) 4.6 (2-5) 
Anxious 4.6 (2-6) 4.3 (1-7) 4.8 (1-6) 
Hyperthymic 11.8 (8-15) 13.8 (11-15) 12.9 (11-14) 
Cyclothymic 3.5 (1-7) 4.2 (1-7) 3.9 (1-5) 
BFI-44 (Big Five Questionnaire)    
Extraversion 3.6 (3.1-4) 3.9 (3.5-4.2) 3.7 (3.4-4.2) 
Agreeableness 3.8 (3.2-4.2) 3.9 (3.4-4.2) 3.8 (3.6-4.4) 
Conscientiousness 3.8 (0.7) 4.1 (0.5) 4.1 (0.5) 
Neuroticism 2.5 (2.2-2.7) 2.3 (1.7-2.9) 2.3 (1.9-2.6) 
Openness 4.0 (0.8) 4.1 (0.4) 4.0 (0.6) 
Berkeley Expressivity 
Questionnaire 
   
Overall emotional 
expressivity 
75 (71-84) 66.8 (57-75) * 65.7 (60-73) 
Negative emotionality facet 26 (5.2) 22 (7.7) * 22.1 (6.9) 
Positive emotionality facet 23.4 (4.1) 22.96 (4.2) 21.4 (4.8) 
Impulse strength facet 24.7 (7.7) 21.8 (7.2) 22.2 (8.4) 
The Pain Vigilance and 
Awareness Questionnaire 
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Sum 38.8 (13.3) 45.5 (13.6) 42.8 (14) 
 
Continuous data are presented as mean (± SD) or means (25-75 percentiles). BDI: Beck 
Depression Inventory; HAM-A: Hamilton Anxiety Scale; SCL-90-R: SCL-90 
autoquestionnaire; GSI: global severity index; PSDI: positive symptom distress index; PST: 
positive symptom total. TEMPS-A: Temperament Evaluation of Memphis, Pisa, Paris and 
San Diego Autoquestionnaire; BFI-44: The Big Five Inventory; Obs-comp: obsessiveness-
compulsiveness; * p<0.05 between CONT-HT1; # p<0.05 between HT1-HT2.  
 
